P&G Signs a License Agreement with Rhinostics to Launch its Novel Nasal Swab into the Market for Rapid COVID-19 Testing and Address Supply Shortages
Shots:
- Rhinostics plans to register the P&G polypropylene nasal swab as a Class I Exempt medical device and will pursue Emergency Use Authorization for home collection with rPT-PCR testing for detection of SARS-CoV-2 infection
- Rhinostics Standard Nasal Swab is a polypropylene collection device developed in partnership with P&G for COVID-19 testing which provides sample concentration of up to 30-fold over other swabs in viral transport media
- The swab increases COVID testing efficiencies being applicable to broader respiratory viral- bacterial- and genetic testing using the PCR and NGS
Ref: Businesswire | Image: Packaging Europe
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com